Perspective Therapeutics presented updated interim data from its Phase 1/2a trial of the lead‑alpha radiopharmaceutical [212Pb]VMT‑α‑NET at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, California, on April 20, 2026. The presentation, led by Chief Medical Officer Markus Puhlmann, covered safety and efficacy outcomes for 64 patients who received at least one dose, with a data cut‑off of March 4, 2026.
Safety results were consistent with earlier reports, showing no dose‑limiting toxicities, no treatment‑related discontinuations, and no clinically significant myelosuppression. The absence of new safety signals across 64 patients reinforces the tolerability of the 5 mCi Cohort 2 dose and supports the continued enrollment of additional dose cohorts.
Efficacy data were presented for 25 patients in Cohort 2 (5 mCi per dose) and two patients in Cohort 1 (2.5 mCi). Among the 25 Cohort 2 patients, 76 % remained progression‑free and 39 % achieved objective responses by RECIST v1.1. The high progression‑free rate and objective response rate, relative to historical controls for gastro‑enteropancreatic neuroendocrine tumors, suggest that the alpha‑particle payload delivers potent tumor cell killing while sparing normal tissue.
Puhlmann noted that the updated analyses continue to support the compelling overall clinical profile of [212Pb]VMT‑α‑NET as a treatment for GEP‑NETs at the Cohort 2 dose level of 5 mCi per dose or up to 20 mCi cumulatively. He added that the company is expanding the trial with additional dose cohorts and is looking beyond GEP‑NETs, indicating a broader therapeutic strategy for the alpha‑particle platform.
Perspective Therapeutics has secured a cash runway into late 2027, with $145 million in cash and investments and a $164 million equity offering completed in February 2026. The continued clinical progress, combined with the company’s proprietary 212Pb generator technology and regional manufacturing network, positions it to scale production if regulatory approval is achieved.
The updated interim data reinforce Perspective’s alpha‑particle platform as a promising modality for targeted radiotherapy and strengthen the company’s pipeline momentum. The results provide a critical data point that will inform the next phase of clinical development and potential regulatory submissions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.